Abstract Library

#3767 Metabolic alterations in patients with pheochromocytoma/paragangliomas and SDHB mutations

Introduction: Pheochromocytoma/paragangliomas (PPGL) patients with SDHB mutation may have unfavourable course of disease. SDHB gene inactivation results in up-regulation of glycolytic reaction and activation of pseudo-hypoxic phenotype in preclinical studies.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Cannavale G, Liccardi A, Minotta R, Modica R,

Keywords: pheochromocytoma, paraganglioma, SDHB,

#3150 A case report of familial paraganglioma syndrome type 4 caused by the SDHB mutation gene

Introduction: Paraganglioma type 4 syndrome is associated with SDHB mutation with a higher risk of malignancy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Ciobanu O, Lambrescu I, Leca B, Nistor I, Martin S,

Keywords: paraganglioma, sdhb mutation,

#2972 Characteristics and Management of Paragangliomas, 10 Years Experience

Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sardo E, Cameselle-Garcia S, Casteras A, Toledo R, Acosta D,

Keywords: Paraganglioma, SDHB mutations, Functioning Tumors,

#1833 Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder

Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Steyn R, Prasad V,

Keywords: SDHB, Bladder PGL, PRRT ,

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,